These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 28529561)
1. Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma. Li X; Yan J; Fan R; Luo B; Zhang Q; Lin Y; Zhou S; Luo G; Xie X; Xiao S Oncol Lett; 2017 May; 13(5):3080-3086. PubMed ID: 28529561 [TBL] [Abstract][Full Text] [Related]
2. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Luo B; Yun X; Li J; Fan R; Guo WW; Liu C; Lin YD; Ge YY; Zeng X; Bi SQ; Nong WX; Zhang QM; Xie XX Curr Med Sci; 2020 Aug; 40(4):719-728. PubMed ID: 32862383 [TBL] [Abstract][Full Text] [Related]
3. Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer: its relationship to clinicopathological parameters. Luo B; Yun X; Fan R; Lin YD; He SJ; Zhang QM; Mo FR; Chen F; Xiao SW; Xie XX Int J Clin Exp Pathol; 2013; 6(12):2835-45. PubMed ID: 24294369 [TBL] [Abstract][Full Text] [Related]
4. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Tammela J; Uenaka A; Ono T; Noguchi Y; Jungbluth AA; Mhawech-Fauceglia P; Qian F; Schneider S; Sharma S; Driscoll D; Lele S; Old LJ; Nakayama E; Odunsi K Int J Oncol; 2006 Oct; 29(4):903-10. PubMed ID: 16964386 [TBL] [Abstract][Full Text] [Related]
5. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Ono T; Kurashige T; Harada N; Noguchi Y; Saika T; Niikawa N; Aoe M; Nakamura S; Higashi T; Hiraki A; Wada H; Kumon H; Old LJ; Nakayama E Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3282-7. PubMed ID: 11248070 [TBL] [Abstract][Full Text] [Related]
6. Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays. Fan R; Huang W; Luo B; Zhang QM; Xiao SW; Xie XX Eur J Gynaecol Oncol; 2015; 36(3):298-303. PubMed ID: 26189257 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of OY-TES-1 by RNAi causes cell cycle arrest and migration decrease in bone marrow-derived mesenchymal stem cells. Cen YH; Guo WW; Luo B; Lin YD; Zhang QM; Zhou SF; Luo GR; Xiao SW; Xie XX Cell Biol Int; 2012 Oct; 36(10):917-22. PubMed ID: 22651134 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of cancer/testis antigen OY-TES-1 attenuates malignant behaviors of hepatocellular carcinoma cells in vitro. Fu J; Luo B; Guo WW; Zhang QM; Shi L; Hu QP; Chen F; Xiao SW; Xie XX Int J Clin Exp Pathol; 2015; 8(7):7786-97. PubMed ID: 26339343 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry Study of OY-TES-1 Location in Fetal and Adult Human Tissues. Fu J; Yingying Ge ; Qingmei Zhang ; Lin Y; Liu C; Nong W; Luo X; Xiao S; Xie X; Luo B J Healthc Eng; 2022; 2022():7052830. PubMed ID: 35463688 [TBL] [Abstract][Full Text] [Related]
10. Identification of an HLA-A24-restricted OY-TES-1 epitope recognized by cytotoxic T-cells. Okumura H; Noguchi Y; Uenaka A; Aji T; Ono T; Nakagawa K; Aoe M; Shimizu N; Nakayama E Microbiol Immunol; 2005; 49(11):1009-16. PubMed ID: 16301813 [TBL] [Abstract][Full Text] [Related]
11. OY-TES-1 may regulate the malignant behavior of liver cancer via NANOG, CD9, CCND2 and CDCA3: a bioinformatic analysis combine with RNAi and oligonucleotide microarray. Hu Q; Fu J; Luo B; Huang M; Guo W; Lin Y; Xie X; Xiao S Oncol Rep; 2015 Apr; 33(4):1965-75. PubMed ID: 25673160 [TBL] [Abstract][Full Text] [Related]
12. Serological analysis of BALB/C methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen. Ono T; Sato S; Kimura N; Tanaka M; Shibuya A; Old LJ; Nakayama E Int J Cancer; 2000 Dec; 88(6):845-51. PubMed ID: 11093803 [TBL] [Abstract][Full Text] [Related]
13. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Ueda R; Iizuka Y; Yoshida K; Kawase T; Kawakami Y; Toda M Oncogene; 2004 Feb; 23(7):1420-7. PubMed ID: 14691456 [TBL] [Abstract][Full Text] [Related]
14. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284 [TBL] [Abstract][Full Text] [Related]
15. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Ueda R; Yoshida K; Kawase T; Kawakami Y; Toda M Int J Cancer; 2007 Apr; 120(8):1704-11. PubMed ID: 17230535 [TBL] [Abstract][Full Text] [Related]
16. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins. Nakada M; Miyamori H; Yamashita J; Sato H Cancer Res; 2003 Jun; 63(12):3364-9. PubMed ID: 12810672 [TBL] [Abstract][Full Text] [Related]
17. Expression of cancer testis genes in human brain tumors. Sahin U; Koslowski M; Türeci O; Eberle T; Zwick C; Romeike B; Moringlane JR; Schwechheimer K; Feiden W; Pfreundschuh M Clin Cancer Res; 2000 Oct; 6(10):3916-22. PubMed ID: 11051238 [TBL] [Abstract][Full Text] [Related]
18. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome. Bai Y; Zhang QG; Wang XH Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses. Monji M; Nakatsura T; Senju S; Yoshitake Y; Sawatsubashi M; Shinohara M; Kageshita T; Ono T; Inokuchi A; Nishimura Y Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6047-57. PubMed ID: 15447989 [TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of TESTIN in primary gastric cancer]. Huang W; Weng DS; Pan ZZ; Pan K; Ding PR; Zhou J; Wang H; Zhang HK; Li JJ; Xia JC Ai Zheng; 2008 Sep; 27(9):984-8. PubMed ID: 18799041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]